# Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

> **NCT06898970** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Varun Monga, MBBS** · enrollment: 18 (estimated)

## Conditions studied

- Angiosarcoma
- Angiosarcoma, Adult

## Interventions

- **BIOLOGICAL:** Vusolimogene Oderparepvec (VO)
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06898970
- **Lead sponsor:** Varun Monga, MBBS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2029-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06898970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06898970, "Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06898970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*